iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF Returns

The iShares U.S. Pharmaceuticals ETF (IHE) outperformed the Simplify Health Care ETF (PINK) over the past year, delivering 42.40% returns versus 29.30%. IHE offers lower costs (0.38% expense ratio), higher dividend yield (1.62%), and focuses on established pharmaceutical giants like Eli Lilly and Johnson & Johnson. While PINK provides active management with innovation focus and donates profits to breast cancer research, its higher expense ratio (0.51%) and recent underperformance give IHE the edge for 2026.

06/10/2026, 2:17 PM • The Motley Fool

These 3 Stocks Lowered Their Share Counts Drastically in Q1

Pinterest, Southwest Airlines, and United Therapeutics executed aggressive share buyback programs in Q1 2026, reducing their outstanding share counts by 16%, 5%, and 3.2% respectively. Pinterest spent $2 billion on repurchases despite being down 15% YTD, while Southwest spent $1.25 billion amid fuel cost headwinds. United Therapeutics utilized a $1.5 billion accelerated share repurchase program following positive clinical trial results for its Tyvaso treatment.

06/09/2026, 11:10 AM • Investing

These 3 Stocks Lowered Their Share Counts Drastically in Q1

Pinterest, Southwest Airlines, and United Therapeutics executed aggressive share buyback programs in Q1 2026, significantly reducing their outstanding share counts. Pinterest led with a 16% reduction on $2 billion in repurchases, Southwest reduced shares by 5% with $1.25 billion spent, and United Therapeutics cut shares by 3.2% through a $1.5 billion accelerated repurchase program. All three companies demonstrated confidence in their future prospects through substantial capital allocation to buybacks.

06/09/2026, 10:13 AM • Investing

Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Over 50 pharmaceutical companies are advancing 55+ pipeline drugs for pulmonary arterial hypertension (PAH) treatment. Recent developments include United Therapeutics' ralinepag meeting Phase III endpoints with 55% risk reduction, Gossamer Bio's seralutinib Phase III results, GSK's acquisition of 35Pharma for HS235, and Inhibikase Therapeutics enrolling patients in Phase III IMPROVE-PAH trial. Multiple novel mechanisms of action are being explored to address persistent clinical gaps in PAH management.

05/19/2026, 1:00 PM • GlobeNewswire

Transplants.org Launches as Centralized Education and Navigation Platform for Organ and Stem Cell Transplant Patients

Transplants.org, a new 501(c)(3) nonprofit, launched a technology-first platform to centralize organ and stem cell transplant education and navigation. Backed by over 25 leading U.S. transplant centers and governed by transplant directors from major medical institutions, the platform uses AI to transform thousands of pages of research materials into accessible patient resources. The initiative addresses a critical gap in fragmented transplant knowledge for the 103,000+ Americans currently waiting for organ transplants.

05/05/2026, 8:00 AM • GlobeNewswire

Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight

The interstitial lung disease market is projected to grow at a CAGR of 8.7% from 2026-2036, driven by emerging therapies and pipeline candidates. The market was valued at USD 6 billion in 2025 across seven major markets, with the US accounting for 83% of the market. Key developments include FDA approval of nerandomilast (JASCAYD) for progressive pulmonary fibrosis and multiple late-stage candidates addressing immune dysregulation and fibrotic signaling.

04/08/2026, 1:00 PM • GlobeNewswire

Stocks Rise As Powell's Remarks Cool Rate Fears: What's Moving Markets Monday?

U.S. equity markets rebounded from seven-month lows on Monday as President Trump disclosed negotiations with Iran and Fed Chair Powell downplayed imminent rate hikes, calling tariffs a 'one-time price bump.' Treasury yields fell significantly, boosting financial, materials, and real estate sectors. Major indices gained broadly, with the S&P 500 up 0.7%, Dow up 1.1%, and Nasdaq 100 up 0.5%.

03/30/2026, 12:40 PM • Benzinga

Why Is United Therapeutics Stock Soaring Monday?

United Therapeutics stock surged 16.5% in premarket trading after announcing that its TETON-1 Phase 3 study of nebulized Tyvaso (treprostinil) met its primary endpoint, showing significant improvement in lung function for idiopathic pulmonary fibrosis patients. The company plans to seek FDA priority review for a supplemental application by summer 2026. Additionally, the company's ralinepag drug achieved a 55% reduction in clinical worsening events in pulmonary arterial hypertension trials.

03/30/2026, 10:08 AM • Benzinga

United Therapeutics' Trial Shows 55% Drop in Lung Disease Worsening

United Therapeutics (NASDAQ: UTHR) stock gained 3.98% after announcing positive Phase 3 trial results for ralinepag, showing a 55% reduction in clinical worsening events for pulmonary arterial hypertension patients and a 47% increase in clinical improvement odds. The company plans to submit an FDA New Drug Application by mid-2026, with the drug demonstrating good tolerability and no new safety concerns.

03/02/2026, 10:32 AM • Benzinga

United Therapeutics Reports Early Success For External Liver Support In Acute Failure

United Therapeutics announced positive Phase 1 results for miroliverELAP, an external liver assist device developed by its subsidiary Miromatrix Medical. The study of five acute liver failure patients met its primary endpoint of survival with no unexpected serious adverse events. The stock is up 0.44% in premarket trading, with analysts expecting strong Q4 earnings growth.

01/26/2026, 8:55 AM • Benzinga

MannKind Provides Business Updates and 2026 Growth Drivers

MannKind Corporation announced strong 2026 growth catalysts including FDA decisions on Afrezza label updates and pediatric indications, FUROSCIX ReadyFlow Autoinjector approval, and pipeline progress with Nintedanib DPI and Bumetanib DPI. The company closed 2025 with record Q4 revenue exceeding $100 million and completed the acquisition of scPharmaceuticals.

01/08/2026, 8:05 AM • Benzinga

Why a $27 Million Buy Signals New Confidence in Weatherford Stock

Summit Street Capital Management initiated a new $27.3 million position in Weatherford International during Q3, representing 3.74% of their reportable assets under management, signaling potential confidence in the oilfield services company's future prospects.

12/09/2025, 3:30 PM • The Motley Fool

Signet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy?

Summit Street Capital Management initiated a $25.3 million position in Signet Jewelers, representing 3.5% of its reportable assets, signaling potential value in the company's margin recovery and strategic performance.

12/09/2025, 3:24 PM • The Motley Fool

Nepsis Liquidates $14 Million CyberArk Software (NASDAQ: CYBR) Position: Did the Stock Soar Too High, Too Fast?

Nepsis Inc. fully sold its entire stake in CyberArk Software during Q3 2025, liquidating 34,236 shares worth approximately $13.93 million, potentially due to the stock's high valuation and recent price surge.

10/26/2025, 6:31 PM • The Motley Fool

Artificial Lung Market to Grow at 10.84% CAGR, Hits USD 7.05 Bn by 2034

The artificial lung market is projected to grow from $2.78 billion in 2025 to $7.05 billion by 2034, with a 10.84% CAGR. North America dominates the market, driven by rising respiratory disease prevalence and technological advancements in medical devices.

10/17/2025, 10:00 AM • GlobeNewswire